Which injection should be administered to a patient with chronic liver disease before a large-volume paracentesis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Albumin Injection After Large-Volume Paracentesis

Administer intravenous albumin (20% or 25% solution) at a dose of 6-8 grams per liter of ascites removed when performing large-volume paracentesis (>5 liters) in patients with chronic liver disease. 1

Dosing Algorithm

For Paracentesis >5 Liters

  • Standard dose: 8 g albumin per liter of ascites removed 1
  • Infuse after the paracentesis is completed, not before
  • Use 20% or 25% albumin solution (high-quality evidence, strong recommendation) 1

Example calculations:

  • 6 liters removed = 48 grams albumin (approximately 240 mL of 20% solution)
  • 8 liters removed = 64 grams albumin (approximately 320 mL of 20% solution) 2

For Paracentesis <5 Liters

  • Consider albumin in high-risk patients: 1, 3
    • Those with acute-on-chronic liver failure (ACLF)
    • Pre-existing hypotension
    • Renal insufficiency (creatinine >1.5 mg/dL)
    • Electrolyte abnormalities
    • History of post-paracentesis complications
  • Use same dose: 6-8 g/L of ascites removed 3, 4

Why Albumin Matters

The rationale is prevention of post-paracentesis circulatory dysfunction (PPCD), which occurs when large-volume fluid removal triggers:

  • Reduced effective arterial blood volume
  • Activation of renin-angiotensin-aldosterone system
  • Sympathetic nervous system activation
  • Risk of acute kidney injury, hyponatremia, hepatic encephalopathy, and death 2, 3

High-quality evidence shows albumin reduces:

  • PPCD by 61% 5
  • Hyponatremia by 42% 5
  • Mortality by 36% 5

Important Caveats

Volume Considerations

  • Limit single-session paracentesis to <8 liters when possible 2
  • Risk of PPCD increases substantially with >8 L removal
  • If more fluid needs removal, consider staged procedures

Albumin Administration

  • Infuse slowly to prevent cardiac overload, especially in patients with cirrhotic cardiomyopathy 5
  • Monitor for volume overload signs (dyspnea, pulmonary edema)
  • Watch for allergic reactions, though rare 6

Emerging Evidence on Lower Doses

Recent studies suggest 4-6 g/L may be equally effective 7, 8, 9, but current guidelines maintain 6-8 g/L as the standard 1, 2, 3. The 2021 Gut guidelines (highest quality) provide high-quality evidence for the 8 g/L dose 1. Until definitive dose-response studies confirm safety of lower doses across diverse populations, adhere to guideline-recommended dosing.

What NOT to Do

  • Do NOT routinely check PT/INR or platelet count before paracentesis 1
  • Do NOT give prophylactic blood products for coagulopathy 1
  • Do NOT use alternative plasma expanders (dextran, gelatin, hydroxyethyl starch) - these carry risks of prion transmission, allergic reactions, and renal impairment 1

Cost-Effectiveness Note

While albumin is expensive and in worldwide shortage 1, it remains the only recommended plasma expander with proven mortality benefit. Standardized order sets can reduce overuse (from 8.3 g/L to 6.5 g/L) without compromising safety 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.